COPENHAGEN, DENMARK, Dec 17th, 2025 – Biograil ApS, a Copenhagen based biotech company developing a unique oral device for delivery of therapeutics that would otherwise have to be injected, announced the strengthening of the board of directors by the addition of Robert (Bob) S. Radie, and Ulrik Schulze.
Bob Radie is an experienced entrepreneur and executive in the pharmaceutical and device space with several successful exits in addition to a long commercial background with 19 years at Lilly. Bob is currently Chairman and CEO at Neuraptive Therapeutics who are advancing a novel drug/device product for nerve repair. Bob was the former CEO of Egalet and worked with several team members now in Biograil making the world’s first injection molded oral product getting FDA approval and receiving market authorization. Bob also serves as Chairman and Director in several biotech companies.
Ulrik Schulze joins the Biograil board from a distinguished 28-year career at the Boston Consulting Group where he held numerous leadership roles, most recently as the Global Leader of the Biopharma Sector. He brings extensive experience in biopharma innovation, go-to-market and M&A. He previously co-founded and was Chairman of ReproNovo SA, a Swiss reproductive health company and serves on the boards of several promising biotech companies.
Biograil CEO Karsten Lindhardt said: “Besides attracting very talented new employees it is great to see a growing board with excellent and complementary competencies to support the Biograil progress. I am very excited to welcome Bob and Ulrik to the Biograil board.”
Bob Radie said: “I have followed Biograil’s progress from the sideline for several years and I am very impressed with how Karsten and the rest of the Biograil team have advanced the BIONDD® technology. I am thrilled to join as a member of the board, and I believe my competencies and experiences can complement the Company as it progresses into clinical development and beyond.”
Ulrik Schulze commented: “The use of injective medicines continues to grow, yet many patients are uncomfortable with injecting themselves, and injections tend to be associated with higher costs for the health care system. Biograil’s BIONDD® technology offers a simple and elegant solution to both challenges. I look forward to applying my extensive experience working with global pharmaceutical and biotech companies to advance Biograil and bringing this exciting technology to patients.”
About Biograil Aps Biograil is a Copenhagen based biotech company developing pharmaceutical products based upon the BIONDD® device contained in a standard size capsule able to deliver active therapeutics into the gastrointestinal wall to be effectively distributed in the human body. Such therapeutics can be currently marketed products, including multi-billion-dollar injectable pharmaceuticals or new chemical entities that cannot otherwise be delivered orally. The Biograil device uses a novel mechanism to facilitate the delivery of active substances i.e., biologics, efficiently into the gastrointestinal wall utilizing a proprietary platform technology manufactured by injection molding. The team behind Biograil is a combination of seasoned entrepreneurs with extensive experience in creating successful biotech companies as well as R&D executives behind the world’s first injection molded oral tablet approved by the FDA. The Biograil investor syndicate is formed by Megatrend Invest (Denmark), Verve Investment, High-Tech Gründerfonds, Eli Lilly and Co., Sanner Ventures, Evonik Venture Capital, Acondis and Roquette Ventures.
